Initial non-curative treatment for favorable intermediate-risk prostate cancer.
1/5 보강
[OBJECTIVE] To compare the oncologic outcomes of intermediate-risk prostate cancer (FIR-PCa) patients receiving different initial treatment regimens as more FIR-PCa patients are now recommended for no
- p-value p < 0.0001
- p-value p = 0.0027
- 95% CI 1.97-5.67
APA
Chen Y, Shangguan X (2026). Initial non-curative treatment for favorable intermediate-risk prostate cancer.. International urology and nephrology, 58(3), 889-894. https://doi.org/10.1007/s11255-025-04768-9
MLA
Chen Y, et al.. "Initial non-curative treatment for favorable intermediate-risk prostate cancer.." International urology and nephrology, vol. 58, no. 3, 2026, pp. 889-894.
PMID
40866735 ↗
Abstract 한글 요약
[OBJECTIVE] To compare the oncologic outcomes of intermediate-risk prostate cancer (FIR-PCa) patients receiving different initial treatment regimens as more FIR-PCa patients are now recommended for non-radical treatment due to the side effects of radical therapy.
[METHODS] 8616 FIR prostate cancer patients were retrospectively evaluated using the Surveillance, Epidemiology, and End Results (SEER) database (2010-2015) and reported prostate cancer-specific survival (PCSS) for groups defined by the initial treatment category. Statistical analysis was performed using Pearson's chi-square test, Multivariate Cox proportional hazard regression, and Kaplan-Meier method.
[RESULTS] Kaplan-Meier curves of PCSS revealed that non-curative treatment provided worse disease control than curative management for FIR-PCa patients (Hazard ratio 5.9061; 95% confidence interval 3.3398-10.4446; p < 0.0001). After adjusting for age at diagnosis, race, T stage, PSA level, and Gleason score, non-curative management was significantly associated with a decrease in PCSS (Adjusted hazard ratio 3.34; 95% CI 1.97-5.67; p = 0.0027).
[CONCLUSION] Pending prospective validation, our findings do not support a 'uniform' increment in current utilization practices for non-curative treatment strategies for FIR-PCa.
[METHODS] 8616 FIR prostate cancer patients were retrospectively evaluated using the Surveillance, Epidemiology, and End Results (SEER) database (2010-2015) and reported prostate cancer-specific survival (PCSS) for groups defined by the initial treatment category. Statistical analysis was performed using Pearson's chi-square test, Multivariate Cox proportional hazard regression, and Kaplan-Meier method.
[RESULTS] Kaplan-Meier curves of PCSS revealed that non-curative treatment provided worse disease control than curative management for FIR-PCa patients (Hazard ratio 5.9061; 95% confidence interval 3.3398-10.4446; p < 0.0001). After adjusting for age at diagnosis, race, T stage, PSA level, and Gleason score, non-curative management was significantly associated with a decrease in PCSS (Adjusted hazard ratio 3.34; 95% CI 1.97-5.67; p = 0.0027).
[CONCLUSION] Pending prospective validation, our findings do not support a 'uniform' increment in current utilization practices for non-curative treatment strategies for FIR-PCa.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Male
- Prostatic Neoplasms
- Retrospective Studies
- Aged
- Middle Aged
- SEER Program
- Neoplasm Grading
- Kaplan-Meier Estimate
- Prostatectomy
- Neoplasm Staging
- Risk Assessment
- Proportional Hazards Models
- Prostate-Specific Antigen
- Survival Rate
- Curative management
- End Results
- Epidemiology
- Favorable intermediate-risk prostate cancer
- Non-curative treatment
- Surveillance
같은 제1저자의 인용 많은 논문 (5)
- A New Algorithm for Secondary Repair of Unilateral Cleft Lip Nasal Deformity.
- Machine-Learning Prediction of Capsular Contraction after Two-Stage Breast Reconstruction.
- DIAPH3 is a multifaceted prognostic biomarker that links immunotherapy response to tumor microenvironment in prostate cancer.
- The Exosome-Lactate-Lactylation Axis: A Metabolic-Epigenetic Circuit Driving Tumor Immune Evasion.
- LncRNAs: key regulators and molecular mechanisms in lung cancer radiosensitivity.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.